RNAi silencing of c-Myc inhibits cell migration, invasion, and proliferation in HepG2 human hepatocellular carcinoma cell line: c-Myc silencing in hepatocellular carcinoma cell

Cancer Cell International

Cong-Jun Wang²  Hui Zhang²  Zhu-Qing Zhou²  Yong-Kun Wang²  Ya-Xin Zheng²  Wei Gao²  Wang Jian²  Yan Zhao¹ 

[1] Department of Gastroenterology, Shanghai Tenth People Hospital, Tongji University School of Medicine, Shanghai, 200072, PR. China;Department of General Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, PR. China

关键词: siRNA;    RNAi;    HepG₂ cells;    Hepatic cancer;    C-Myc;   

Others  :  794191
DOI  :  10.1186/1475-2867-13-23

 received in 2012-07-28, accepted in 2013-01-29,  发布年份 2013

【 摘 要 】

Background

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Although much is known about both the cellular changes that lead to HCC and the etiological agents responsible for the majority of HCC cases, the molecule pathogenesis of HCC is still not well understood. We aimed to determine the effect of c-Myc gene expression on the proliferative, invasive, and migrative capabilities of hepatocellular carcinoma HepG₂ cells.

Methods

A plasmid- based polymerase III promoter system was used to deliver and express short interfering RNA targeting c-Myc to reduce its expression in HepG₂ cells. Western blot analysis was used to measure the protein level of c-Myc in HepG₂ cells. The effects of c-Myc silencing on the invasion, motility, and proliferation of HepG₂ cells were assessed using a Transwell chamber cell migration assay system and a growth curve assay, respectively.

Results

The data showed that plasmids expressing siRNA against c-Myc significantly decreased its expression in HepG₂ cells by up to 85%. Importantly, pSilencer-c-Myc transfected cells showed a significantly reduced potential in migration, invasion, and proliferation.

Conclusion

C-Myc plays an important role in the development of hepatocellular carcinoma. The data show that down-regulating the c-Myc protein level in HepG₂ cells by RNAi could significantly inhibit migration, invasion and proliferation of HepG₂ cells. Thus, c-Myc might be a potential therapeutic target for hepatocellular carcinoma.

【 授权许可】

   
2013 Zhao et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 2.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Vinay K, Abbas A, Fauston N: Robbins and Cotran pathologic basis of disease. New York: Saunders; 2004:623-625.
• [2]Dawe RS: Hepatocellular carcinoma. Lancet 2004, 363(9412):899.
• [3]Thorgeirsson SS, Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31(4):339-346.
• [4]Hunecke D, Spanel R, Länger F, Nam SW, Borlak J: MYC‐regulated genes involved in liver cell dysplasia identified in a transgenic model of liver cancer. J Pathol 2012, 228(4):520-533.
• [5]Möröy T, Marchio A, Etiemble J, Trépo C, Tiollais P, Buendia MA: Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks. Nature 1986, 324(6094):276-279.
• [6]Lin CP, Liu CR, Lee CN, Chan TS, Liu HE: Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol 2010, 2(1):16.
• [7]Terradillos O, Billet O, Renard CA, Levy R, Molina T, Briand P, Buendia MA: The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 1997, 14(4):395.
• [8]Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, Gambhir SS, Felsher DW: MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res 2011, 71(6):2286-2297.
• [9]Peng S, Lai P, Hsu H: Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. J Formos Med Assoc 1993, 92(10):866.
• [10]Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI: Modelling Myc inhibition as a cancer therapy. Nature 2008, 455(7213):679-683.
• [11]Xu Y, Wang Y, Gao J, Ye J, Zhu H, Xu N, Wang X, Sun Z: Suppression of c-myc expression by interference RNA in HepG2 hepatocellular carcinoma cells. Zhonghua Zhong Liu Za Zhi 2004, 26:458-460.
• [12]Gearhart J, Pashos EE, Prasad MK: Pluripotency redux—advances in stem-cell research. N Engl J Med 2007, 357(15):1469-1472.
• [13]Cotterman R, Jin VX, Krig SR, Lemen JM, Wey A, Farnham PJ, Knoepfler PS: N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res 2008, 68(23):9654.
• [14]Chiu YL, Ali A, Chu C, Cao H, Rana TM: Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 2004, 11(8):1165-1175.
• [15]Iorns E, Lord CJ, Turner N, Ashworth A: Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007, 6(7):556-568.
• [16]Yan B, Wang ZH, Guo JT: The research strategies for probing the function of long noncoding RNAs. Genomics 2011, 99(2):76-80.
• [17]Dykxhoorn DM, Novina CD, Sharp PA: Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003, 4(12):7-17.
• [18]Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411(6836):494-498.
• [19]Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA: Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 2001, 98(17):9742-9747.
• [20]Niu XY, Peng ZL, Duan WQ, Wang H, Wang P: Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer 2006, 16(2):743-751.
• [21]Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003, 9(3):931-946.